BioSpace News Archive

The Transaction continues to realize on the Board’s commitment to grow globally through strategic acquisitions.

Hepa Wash’s U.S. expansion will be guided by a team of GALS mentors with profound commercial and technical expertise in the field of organ support.

CA-008 is a proprietary water-soluble prodrug that converts into capsaicin, a potent TRPV-1 agonist.

Gecko’s proprietary technology platform is composed of fully synthetic light-activated polymers that can be ‘printed’ on living tissue inside and outside the body.

The purpose of this event is to promote quality awareness and provide continuing education on quality systems and processes at NAI.

Astellas’ Walt Johnston has been elected as chairman of the iBIO and iBIO Institute Boards of Directors. He succeeds Timothy P Walbert, Horizon Pharma, who served as chairman for the past two years and who will continue to serve on the Board and Executive Committee as Immediate Past Chairman.

The radiology sites specialize, among other things, in detecting and characterising musculotendinous and mammary lesions, and diagnosing abdominal diseases with 14 radiologists who conduct all of the diagnostic and therapeutic exams.

The late-breaking data presentation will include positive topline results from the Phase III HERCULES study of caplacizumab announced on 2 October 2017 together with important data from additional analyses on the use of plasma exchange.

The Phase 2 data were presented at the 2017 San Antonio Breast Cancer Symposium (SABCS) being held December 5-9, 2017 in San Antonio, Texas.

Syros announced that new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor currently in a Phase 1 clinical trial in advanced solid tumors, demonstrate anti-tumor activity across a broad panel of breast cancer cell lines and point to potential biomarkers predictive of response.